Judge tries to broker treatment deal for patients with macular degeneration in funding row

BMJ 2008; 337 doi: (Published 16 July 2008) Cite this as: BMJ 2008;337:a864
  1. Clare Dyer
  1. 1BMJ

    The judge presiding over a legal challenge to a primary care trust’s refusal to fund sight saving drugs on the NHS has adjourned the case in an attempt to broker a deal.

    Mr Justice Forbes, sitting at the High Court in London, called on Novartis, manufacturer of ranibizumab (Lucentis), to try to work out an agreement with Warwickshire Primary Care Trust (PCT) so that the three patients who have brought the case to court can get the drug before their sight deteriorates further.

    The …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to to receive unlimited access to all content on for 14 days.
    Sign up for a free trial